Glucose Concentrations Less Than 54 mg/dL Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

December 2016. The American Diabetes Association and the European Association for the Study of Diabetes have released a statement agreeing that glucose levels lower than 54 mg/dL (3.0 mmol/L) should be reported in clinical trials evaluating drugs for the treatment of diabetes. This position statement outlines the groups’ decision-making process and rationale for selecting this threshold and also indicates that hypoglycemia levels of less than 70 mg/dL do not need to be routinely reported in clinical trials. Click here for full article